The Medipattern Corporation
TSX VENTURE : MKI

The Medipattern Corporation

June 23, 2009 12:21 ET

Medipattern Signs B-CAD-FOR-LIFE™ Agreement With Long Island Radiology Associates

TORONTO, ONTARIO--(Marketwire - June 23, 2009) - The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, announced today that Long Island Radiology Associates (LIRA) has entered into a B-CAD-FOR-LIFE™ contract. LIRA has seven (7) facilities in the greater New York City area and on Long Island. B-CAD-FOR-LIFE provides all of the separate components that are required to install, train, use and maintain B-CAD under one monthly service fee. Since its introduction in mid-February 2009, demand for this alternative, cost effective solution has steadily increased.

"We are impressed with B-CAD's clinical value. B-CAD creates a concise synopsis of the case with a breast map showing the location, description and pictures where the lesion is highlighted by CAD," commented Linda Bolger, Director of Managed Care. "We have a large multi-site practice. Our dedicated team is focused on our patients, which means that communication between team members can be brief. B-CAD ensures that we fill in the gaps for consistent communication and improved healthcare. B-CAD will give us an advantage in our fight against breast cancer. At Long Island Radiology, we care about preventive healthcare for women. We offer a full range of state-of-the-art women's imaging services."

"Current National Cancer Institute figures show that the breast cancer incidence rate for the two counties on Long Island are elevated by 8.5 percent to 11.7 percent higher than the U.S. national average(1). The practices on Long Island know full well that they are operating in an environment where the odds are stacked against their patients and they strive to take full advantage of technology to help them find and correctly identify breast cancer earlier while it is more treatable. LIRA believes that B-CAD gives them an advantage and are pleased that they can access B-CAD through the B-CAD-FOR-LIFE program," added Jeff Collins, CEO of The Medipattern Corporation. "B-CAD-FOR-LIFE has enabled facilities to take advantage of our software and gain its benefits even in these tough economic conditions. We welcome LIRA to the B-CAD family. We congratulate our reseller Amy Eriksen of Physician's Consultant Medical Sales for facilitating this transaction."

2009 Upcoming Events:

- BIC (Breast Imaging Conference), September 4-5, 2009 in Nashville, TN partnered with GE

- International Breast Symposium, October 1-4, 2009 in Chicago, IL

- RSNA (Radiological Society of North America), November 29 to December 3, 2009, Chicago, IL



(1) According to National Cancer Institute data, the U.S. national breast
cancer incidence rate is 127.8 per 100,000 patients. Nassau County
exceeds the U.S. national incidence rate by 10.9 cases per 100,000,
and Suffolk County exceeds it by 14.9 cases per 100,000.


About The Medipattern Corporation:

Medipattern® (TSX VENTURE:MKI) is a pioneer in the development of medical software solutions that help improve imaging workflow and productivity. Our first-to-market, award-winning B-CAD® advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its Cadenza™ CAD Technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective. For more information, please visit the Company's website at: www.medipattern.com.

B-CAD® and Medipattern® are a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates,'' "believes,'' "estimates,'' "expects,'' "plans,'' "intends,'' "potential'', and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information